Radiopharm (RADX) Theranostics announced the dosing of the first patient in its Phase 1 ‘HEAT’ clinical trial of RAD202, a proprietary nanobody that targets Human Epidermal Growth Factor Receptor 2-positive expression in a wide array of advanced solid tumors. The open-label Phase 1 “HEAT’ clinical trial is a dose escalation trial of 177Lu-RAD202 that is designed to determine the recommended Phase 2 dose and to evaluate the safety and preliminary clinical activity of this novel radiotherapeutic in individuals with HER2-expressing advanced cancers. The study is currently being conducted at clinical centers across Australia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
- Radiopharm reports preclinical Lu177-B7H3-mAb data
- Radiopharm pipeline ‘dramatically’ undervalued, says JonesResearch
- Radiopharm Theranostics Secures Lutetium-177 Supply Agreement with ITM
- Radiopharm, ITM sign supply agreement for n.c.a. Lutetium-177
- Radiopharm says DSMC says Phase 1 study may continue as planned